MHRA approves two new medicines for overactive bladder syndrome and breast cancer
Pierre Fabre Limited receives MHRA marketing authorisation for vibegron, Astra Zeneca UK Limited for Capivasertib
The Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday,...
Breast Cancer survivors face heightened risk of second cancers, new research reveals
Higher risks of breast cancer and second primary cancers for individuals residing in areas of greater socioeconomic deprivation
A groundbreaking study analysing data from nearly...
Drugs to Watch 2024: Here are 13 potential blockbuster therapies expected to launch this year
In addition, Clarivate report highlights some new technology platforms that are likely to achieve significant proof of medical use in the market in 2024
Information...
‘Repurposed’ NHS drug could help prevent thousands of women from breast cancer
The drug can 'reduce' breast cancer incidence in post-menopausal women by almost 50 per cent
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Anastrozole...
NICE recommends Enhertu for advanced breast cancer
The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer.
“There is not enough evidence yet to...
NHS introduces ‘Pembrolizumab’ to treat triple-negative breast cancer
The NHS has secured a deal for ‘Pembrolizumab’ to treat women with triple-negative breast cancer.
Up to 1,600 women a year affected by high risk...